Skip to main content
Premium Trial:

Request an Annual Quote

DeCode's Q4 Revenues Rise 17 Percent as Loss Grows on Increased R&D Costs

NEW YORK (GenomeWeb News) — DeCode Genetics today said fourth-quarter revenues increased 17 percent as R&D spending rose 4 percent and lossed increased 10 percent.
 
Total receipts for the three months ended Dec. 31, 2006, rose to $11.5 million from $9.8 million year over year. DeCode said it has $9.8 million in deferred revenue which will be “recognized over future reporting periods.”
 
R&D spending increased to $14.2 million from $13.7 million year over year.
 
The company said losses increased to $23.2 million from $21.1 million in the year-ago period.
 
The increase in losses came from increased selling and other costs, and on increased R&D spending for clinical trials of the company’s arterial thrombosis and heart attack drugs, which are in Phase IIa and Phase I trials, respectively.
 
DeCode said it had around $152 million in cash and investments as of Dec. 31.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.